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Abstract: The macrocyclization of linear peptides is very often
accompanied by significant improvements in their stability and
biological activity. Many strategies are available for their
chemical macrocyclization, however, enzyme-mediated meth-
ods remain of great interest in terms of synthetic utility. To date,
known macrocyclization enzymes have been shown to be
active on both peptide and protein substrates. Here we show
that the macrocyclization enzyme of the cyanobactin family,
PatGmac, is capable of macrocyclizing substrates with one,
two, or three 1,4-substituted 1,2,3-triazole moieties. The
introduction of non-peptidic scaffolds into macrocycles is
highly desirable in tuning the activity and physical properties of
peptidic macrocycles. We have isolated and fully characterized
nine non-natural triazole-containing cyclic peptides, a further
ten molecules are also synthesized. PatGmac has now been
shown to be an effective and versatile tool for the ring closure
by peptide bond formation.
Macrocycles in general and peptidic macrocycles in partic-
ular have recently gained more attention since they have been
identified as potential sources for novel therapeutics.[1] These
compounds, abundant in nature, are known to possess a wide
range of biological activities.[1,2] They owe their attractiveness
to having higher structural rigidity and better chemical
stability, especially against hydrolysis and peptidase activity
in the case of peptide-based macrocycles.[3] The increased
molecular weight of these compounds is usually balanced by
their increased specificity and selectivity towards the targets
compared to “small” molecules.[4] Patellamides are natural
cyclic octapeptides that belong to the large family of
cyanobactins.[5] Their biosynthesis consists of the modification
of a long precursor peptide via the action of different tailoring
enzymes to achieve heterocyclization of cysteines, or threo-
nines and serines to thiazoline or oxazoline, proteolysis,
macrocyclisation, epimerization of certain amino acids, oxi-
dation of the heterocycles, and in some cases prenylation.[6]
Although many natural peptidic macrocycles have some
side chain modifications, (e.g. sugars, prenyl, lipid), it would
appear that it is relatively rare in nature, to have both amino
acids and non-peptidic molecules forming the macrocyclic
backbone. Nonetheless, the synthesis of such compounds
would be greatly beneficial for complementary SAR studies
on different targets.[2b] A restriction to the natural amino acid
building blocks in these cyclic peptides limits the diversity and
thus the chemical properties and activities that such mole-
cules can possess. A partial solution to this problem comes
from the use of non-natural amino acids in biological systems
in vivo or in vitro,[7] which have already been demonstrated
for peptidic macrocycles[8] (Figure 1). Hybrid molecules have
Figure 1. PatGmac macrocylized compounds. a) The natural com-
pound, patellamide D. b–d) Examples of previously synthesized non-
natural cyclic compounds.[8a–c] e) This study; n represents the number
of triazole units in the sequence; the molecule number represents the
position of the triazole (Tz) moiety/moieties in the core peptide (i.e.
Cyclo(-VTzGAGIGFP) is CP1). The highlighted heterocycle in grey is C-
terminal in the core peptide. The bold parts of the molecules represent
the non-natural modifications to the core peptide. Ahp: 7-aminohepta-
noic acid. (Thz): thiazoline heterocycle.
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gained significant attention through the use of the so called
stapled peptides,[9] but in this case, the non-peptidic module
tends to be chosen to lock the peptide in a specific con-
formation rather than being a key component for activity.
The ring closure of peptidic macrocycles can be achieved
either chemically[2b,10] or enzymatically with a number of
distinct enzymes known including butelase,[11] POPB,[12]
sortase,[13] recombinant asparaginyl endopeptidase (AEP),[14]
thioesterase,[15] and the macrocyclase enzyme (PatGmac)
from the patellamide family.[8a–c,16] PatGmac recognizes a C-
terminal AYD(G) motif located outside the core of the
precursor peptide substrate and cleaves it to form a water
shielded acyl-enzyme intermediate using its catalytic Asp-
His-Ser triad.[16] The intermediate is then attacked by the free
N-terminal amine of the core peptide. The substrate must
have a thiazoline, oxazoline or a proline immediately N-
terminal to the (cleaved off) AYD(G)[16] motif with no other
restrictions on the rest of the core peptide. This very broad
substrate range has made PatGmac an attractive tool for
biotransformation (Figure 1). We decided to test its ability to
macrocyclize substrates in which non-peptidic motifs are
included in the sequence. We have chosen to investigate the
incorporation of 1,4-substituted 1,2,3-triazole[17] groups into
macrocycles.[18] The triazole ring can act as an isostere for
a trans-amide bond and its synthesis is facile.[19] Further the
triazole moiety has been incorporated in many biologically
active compounds as it is thermodynamically and physiolog-
ically stable.[20]We reasoned therefore this would be a suitable
test of the versatility of PatGmac by systematically incorpo-
rating the triazole unit (Tz) at different positions of the
precursor peptide while varying their number as well. We
report herein the successful formation (catalyzed by PatG-
mac) of macrocycles containing one, two, and three 1,2,3-
triazoles.[21]
A series of 19 different linear precursor peptides P based
on the core sequence VGAGIGFPwere prepared by standard
solid phase peptide synthesis using the Fmoc strategy (see
Supporting Information, SI). The linear peptides VGAGIGF-
PAYD-NH2 consisted of the core sequence modified with one,
two, or three non-consecutive triazoles and the PatGmac
recognition motif AYD with an N-terminal amide. The
triazoles were generated directly on solid phase using
a copper(I) catalyzed azide-alkyne cycloaddition
(CuAAC).[18b] Azido acids 1a,b and 1d were synthesized in
one step by a diazo transfer reaction[22] (Scheme S3).[23] Fmoc
protected amino alkynes 2a–c were synthesized in five steps
starting from the commercial Boc protected amino acid. First,
the Weinreb amides were synthesized by a standard coupling
reaction. The use of DIBAL-H for the amide reduction in
a one pot procedure with the Bestmann–Ohira reagent[24] in
our hands was found to yield very little conversion to the
aldehyde. Separating the two steps with the reduction to
aldehyde using LiAlH4 followed by the Bestmann-Ohira
reagent, successfully afforded the Boc protected amino
alkynes. A final deprotection and protection step afforded
the desired alkynes 2a–c in moderate yields overall
(Scheme S4). The N-terminal azide was attached on the
growing peptide by a standard coupling reaction then was
subjected to the CuAAC reaction with the corresponding
alkyne counterpart 2 on solid phase (Scheme 1; Scheme S1).
Final precursor peptides P1-6 have a single triazole (Tz) at
a different position of the core sequence[25] (the number
denoting the position), precursors P13-16, P24-26, P35-36 and
P46 have two triazoles (i.e. at positions 1 and 3 of the peptide
for P13 ; VTzGATzGIGFPAYD), and P135 and P246 have
three triazoles (Table S1; Table S2). P0 has no triazoles and
was synthesized to serve as a control for the macrocyclization
reaction.
All precursor peptides P were subjected to the macro-
cylization reaction conditions in the presence of PatGmac in
bicine buffer at pH 8.1 and 37 8C. The reaction progress was
monitored by MALDI-MS and some of the resulting spectra
are shown in Figure 2.
All 19 precursor peptides converted to the desired
macrocyclic structure and no significant linear product
(AYD cleavage product) was detected in the reaction
mixture. We observed that two triazole-containing substrates
were slower to macrocyclize than single triazole-containing
peptides and that both three triazole peptides were the
slowest to convert. Nonetheless, because PatGmac is known
to be a slow enzyme, the rate difference is insignificant
(reactions were monitored 20 to 25 days for full conversion on
large scale).[16]
Nine of the precursor peptides, P0, P1, P2, P3, P4, P5, P6,
P13 and P135, were reacted at a larger scale (8 mmol, 9–
10 mg) in the presence of PatGmac under the previously
stated conditions in order to provide sufficient amounts of the
macrocyclic product for full characterization. Cyclic peptides
CP were extracted and HPLC purified to afford moderate
yields of high purity samples. Results are summarized in
Scheme 1. Synthesis of triazole-containing cyclic peptides.
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Tables 1 and S3 (see Scheme 1 or SI, section I for structures).
For some of these (CP3, CP13, CP135), two peaks on the
HPLC had the expected mass of the cyclic peptide in the
crude reaction mixture, as can be seen from the ratio column
in Table 1 (SI, section VIII). When applicable, both peaks
were collected and analyzed by HRMS and MS-MS frag-
mentation patterns and both were determined to be the
desired cyclic peptide (Table S3). However, the NMR experi-
ments were only conducted for the major isolated compound.
The MS-MS fragmentation data of the cyclic peptides
gave a very complex series of ions consistent with their
peptidic sequence, the newly formed valine to proline bond
(macrocycle formation), and the triazole presence (SI,
section VII).
NMR experiments were also conducted in order to further
confirm their structures. The proton NMR data of the cyclic
peptides showed at least two species present at different ratios
depending on the compound. For CP0, CP1, CP2, CP3 CP4,
CP6 and CP13 this was shown by Exchange Spectroscopy
(EXSY) experiments to result from different conformers (SI,
section VI). However, compound CP5 was found to have two
distinct compounds in a 1:0.6 ratio. The NMR assignments of
both species show they have the same peptidic sequence
(cyclic VGAGITzGFP). Both HRMS and MS-MS fragmen-
tation data confirm the presence of one mass/one sequence.
This led us to believe that the two species are most likely
epimers but we cannot exclude structurally rigid conformers
unable to interconvert.[26]
CP135 has a very complex proton and 2D NMR spectra
that showed at least four different species (with two other
minor species). General assignment has been achieved for
most proton peaks (SI, section V) however, the individual
sequence for each was not determined. EXSY showed that
two of them are related conformers and the other two are
distinct compounds. Similarly to compound CP5, these
species would most probably arise from epimers or from
conformationally rigid variants.
Biotransformation is now widely used in organic chemis-
try for the synthesis of biologically relevant compounds. The
PatGmac enzyme is unusual in that it operates on substrates
and disposes of almost the entire recognition site during the
reaction. PatGmac macrocyclizes a wide range of natural
peptidic substrates and tolerates non-natural amino acids.[8a,b]
From a chemical diversity point of view, the ability to mix
amino acid residues and non-amino acid scaffolds within the
backbone of macrocyles is highly desirable. We have now
shown that it is possible to synthesize macrocycles with one,
two, or three triazoles within a peptidic sequence. Thus
PatGmac is able to process peptide hybrid substrates
extending its utility. The ability to macrocyclise such hybrid
molecules highlights the scope for creating highly diverse
libraries through split and pool approaches.
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Figure 2. MALDI-MS traces of the macrocyclization reactions of representative sequences with a) control peptide; VGAGIGFP, 0 triazole, 20 days;
b) VTzGAGIGFP, 1 triazole, 21 days; c) VTzGATzGIGFP, 2 triazoles, 23 days; d) VTzGATzGITzGFP, 3 triazoles, 25 days.
Table 1: PatGmac macrocylization reaction products.
Peptide Core peptide [a] Ratio [%][b] Yield [%][c] Purity [%][d]
CP0 VGAGIGFP 100 32 99
CP1 VTzGAGIGFP 100 43 99
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CP4 VGAGTzIGFP 100 34 98
CP5 VGAGITzGFP 100 58 93
CP6 VGAGIGTzFP 100 40 98
CP13 VTzGATzGIGFP 20/80 54 98
CP135 VTzGATzGITzGFP 15/85 39 97
[a] Tz= triazole replacing the amide bond. [b] Ratio of cyclic products in
crude mixture (SI, section VIII). [c] Total yield. [d] Purity of major product
determined by HPLC, UV absorption at 220 nm (SI, section IX).
Angewandte
ChemieCommunications
5844 www.angewandte.org Ó 2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2016, 55, 5842 –5845
Research Council (K015508/1), The Wellcome Trust (Triple-
TOF 5600 mass spectrometer (094476), the MALDI TOF-
TOFAnalyser (079272AIA), 700 NMR) and the EPSRC UK
National Mass Spectrometry Facility at Swansea University.
J.H.N. is a Royal Society Wolfson Merit Award Holder and
1000 talent scholar at Sichuan University.
Keywords: biotransformation · cyanobactin · cyclic peptides ·
peptidomimetics · triazole
How to cite: Angew. Chem. Int. Ed. 2016, 55, 5842–5845
Angew. Chem. 2016, 128, 5936–5939
[1] a) E. M. Driggers, S. P. Hale, J. Lee, N. K. Terrett,Nat. Rev. Drug
Discovery 2008, 7, 608; b) D. J. Newman, G. M. Cragg in
Macrocycles in Drug Discovery (Eds.: J. R. Morphy, C. J.
Harris), The Royal Society of Chemistry, London, 2015, pp. 1 –
36.
[2] a) A. T. Bockus, C. M. McEwen, R. S. Lokey, Curr. Top. Med.
Chem. 2013, 13, 821; b) X. Yu, D. Sun,Molecules 2013, 18, 6230.
[3] S. H. Joo, Biomol. Ther. 2012, 20, 19.
[4] C. Heinis, Nat. Chem. Biol. 2014, 10, 696.
[5] M. Jaspars, Chem. Commun. 2014, 50, 10174 – 10176.
[6] a) J. Koehnke, A. F. Bent, W. E. Houssen, G. Mann, M. Jaspars,
J. H. Naismith, Curr. Opin. Struct. Biol. 2014, 29, 112 – 121;
b) E. W. Schmidt, J. T. Nelson, D. A. Rasko, S. Sudek, J. A.
Eisen,M. G. Haygood, J. Ravel,Proc. Natl. Acad. Sci. USA 2005,
102, 7315 – 7320.
[7] T. S. Young, P. G. Schultz, J. Biol. Chem. 2010, 285, 11039 –
11044.
[8] a) J. A.McIntosh, C. R. Robertson, V. Agarwal, S. K. Nair, G. W.
Bulaj, E. W. Schmidt, J. Am. Chem. Soc. 2010, 132, 15499 –
15501; b) E. Oueis, C. Adamson, G. Mann, H. Ludewig, P.
Redpath, M. Migaud, N. J. Westwood, J. H. Naismith, Chem-
BioChem 2015, 16, 2646 – 2650; c) D. Sardar, Z. Lin, E. W.
Schmidt, Chem. Biol. 2015, 22, 907 – 916; d) T. Kawakami, A.
Ohta, M. Ohuchi, H. Ashigai, H. Murakami, H. Suga, Nat.
Chem. Biol. 2009, 5, 888 – 890.
[9] A. K. Yudin, Chem. Sci. 2015, 6, 30 – 49.
[10] C. J. White, A. K. Yudin, Nat. Chem. 2011, 3, 509 – 524.
[11] G. K. T. Nguyen, A. Kam, S. Loo, A. E. Jansson, L. X. Pan, J. P.
Tam, J. Am. Chem. Soc. 2015, 137, 15398 – 15401.
[12] H. Luo, S.-Y. Hong, R. M. Sgambelluri, E. Angelos, X. Li, J. D.
Walton, Chem. Biol. 2014, 21, 1610 – 1617.
[13] W. vanÏt Hof, H. M. Silvie, C. I. V. Enno, G. M. B. Jan, Biol.
Chem. 2015, 396, 283 – 293.
[14] K. S. Harris, T. Durek, Q. Kaas, A. G. Poth, E. K. Gilding, B. F.
Conlan, I. Saska, N. L. Daly, N. L. van der Weerden, D. J. Craik,
M. A. Anderson, Nat. Commun. 2015, 6, 6370.
[15] R. M. Kohli, J. W. Trauger, D. Schwarzer, M. A. Marahiel, C. T.
Walsh, Biochemistry 2001, 40, 7099 – 7108.
[16] J. Koehnke, A. Bent, W. E. Houssen, D. Zollman, F. Morawitz, S.
Shirran, J. Vendome, A. F. Nneoyiegbe, L. Trembleau, C. H.
Botting, M. C. M. Smith, M. Jaspars, J. H. Naismith, Nat. Struct.
Mol. Biol. 2012, 19, 767 – 772.
[17] In the rest of the paper, the 1,4-substituted 1,2,3-triazole will be
referred to as triazole.
[18] a) C. W. Tornøe, C. Christensen, M. Meldal, J. Org. Chem. 2002,
67, 3057 – 3064; b) M. Meldal, C. W. Tornøe, Chem. Rev. 2008,
108, 2952 – 3015.
[19] G. C. Tron, T. Pirali, R. A. Billington, P. L. Canonico, G. Sorba,
A. A. Genazzani, Med. Res. Rev. 2008, 28, 278 – 308.
[20] I. Pibiri, S. Buscemi, Curr. Bioact. Compd. 2010, 6, 208.
[21] The replacement of an amide bond by a triazole is represented
by a “Tz” between the corresponding two amino acids in the
sequence.
[22] E. D. Goddard-Borger, R. V. Stick, Org. Lett. 2007, 9, 3797.
[23] Reagant 1e is commercially available. Reagant 2e is easily
prepared from commercial propargylamine.
[24] H. D. Dickson, S. C. Smith, K. W. Hinkle, Tetrahedron Lett. 2004,
45, 5597 – 5599.
[25] The molecule number represents the position of the triazole (Tz)
moiety/moieties in the core peptide (VTzG is position 1, GTzF is
position 6).
[26] J. N. Tabudravu, M. Jaspars, L. A. Morris, J. J. Kettenes-van den
Bosch, N. Smith, J. Org. Chem. 2002, 67, 8593 – 8601.
Received: February 13, 2016
Published online: April 5, 2016
Angewandte
ChemieCommunications
5845Angew. Chem. Int. Ed. 2016, 55, 5842 –5845 Ó 2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
